This review will focus on the development of vaccines against influenza A/H5N1 strains. Reducing the impact of the potential pandemic would entail pharmaceutical and nonpharmaceutical interventions.

Life science companies developing bird flu vaccines and antivirals are gaining attention as the avian influenza subtype H5N1 becomes an increasing concern. The United States is in the midst of an ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

While H5N1 does not have high mortality rates in dairy cows, the infection causes decreases milk production and milk quality, ...

According to the CDC, there has been a decline in animal infections and no reports of human cases since February.

Short sellers started to panic in recent days. Moderna (MRNA), which has a short interest of 16.44%, might benefit from two ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

From the outset of the Trump administration, bird flu, or H5N1 avian influenza, has flown rather conspicuously — and in fact ...

Following a prolonged but ultimately successful application process, South Africa’s largest poultry company has become the ...